Table 2. Characteristics of 17 patients treated with pemafibrate.
| Male/Female | 10:7 | |
| Age (years) | 63 (27–81) | |
| Height (m) | 1.7 (1.5–1.8) | |
| Pre-treatment body weight (kg) | 70.6 (48.6–101.7) | |
| Pre-treatment BMI (kg/m2)* | 26.8 (19.2–33.8) | |
| Patients of BMI > 25 kg/m2 | 11 (64.7%) | |
| Comorbidities | ||
| T2DM | 10 | (58.8) |
| Chronic hepatitis B† | 1 | (5.9) |
| CAD | 1 | (5.9) |
| IBD | 1 | (5.9) |
| GERD | 1 | (5.9) |
| Other‡ | 1 | (5.9) |
| Imaging modalities | ||
| US | 10 | (58.8) |
| CT | 6 | (35.3) |
| MRI | 1 | (5.9) |
| Biopsy proven NASH | 3 | (17.6) |
| Pre-treatment laboratory values | ||
| TG (mg/dL) | 300.5 ± 22.5 | |
| HDL-cholesterol (mg/dL) | 46.5 ± 2.4 | |
| LDL-cholesterol (mg/dL) | 109.5 ± 10.6 | |
| AST (U/L) | 43.8 ± 5.4 | |
| ALT (U/L) | 57.5 ± 8.8 | |
| GGT (U/L) | 63.9 ± 10.3 | |
| FIB-4 index | 1.7 ± 0.2 | |
| APRI | 0.7 ± 0.1 | |
| HbA1c (%) | 7.7 ± 0.5 | |
| Concomitant medications | ||
| DPP4 inhibitor | 6 | (35.3) |
| Metformin | 3 | (17.6) |
| SGLT2 inhibitor | 2 | (11.8) |
| EPA | 3 | (17.6) |
| Statin | 5 | (29.4) |
| Ezetimibe | 7 | (41.2) |
| UDCA | 4 | (23.5) |
| Dosage of pemafibrate | ||
| 0.1 mg | 3 | (17.6) |
| 0.2 mg | 12 | (70.6) |
| 0.4 mg | 2 | (11.8) |
| Duration of pemafibrate administration (months) |
6.1 (3.0–19.1) | |
APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CAD, coronary artery disease; CT, computed tomography; DPP4, dipeptidyl peptidase-4; EPA, eicosapentaenoic acid; GERD, gastroesophageal reflux disease; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; IBD, inflammatory bowel disease; LDL, low-density lipoprotein; MRI, the magnetic resonance of imaging; SGLT2, sodium-glucose cotransporter 2; T2DM, type 2 diabetes mellitus; TG, triglyceride; UDCA, ursodeoxycholic acid; US, ultrasonography. *BMI cannot be calculated in two patients because of a lack of body hight. †HBV DNA is controlled under the detective level by nucleotide analog treatment. ‡Ovarian insufficiency. Data are expressed as median (range) or mean ± SEM.